Business News • PR NewsWire • Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

EAST HANOVER, N.J., Nov. 15, 2014 /PRNewswire/ -- Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis (AS). In the studies, secukinumab met the primary endpoint demonstrating statistically...

View More : http://www.prnewswire.com/news-releases/novartis-ain457-secukinumab-showed-significant-symptom-improvement-in-two-pivota...

Releted News by prnewswire

Bowes Dermatology Offers Non-Invasive Neck Lift With The Revolutionary Velashape III

Moody Gardens Becomes Premiere Holiday Destination In Southwest With Debut Of ICE LAND: Ice Sculptures With SpongeBob SquarePants

Most Successful Condo Launch Since Recession Reflects Explosive Demand in Calgary - Analysts say Demand Outpacing Supply

Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

Unified Communication Market (UC): 14% CAGR Forecast to 2019

AliveCor® to Showcase the AliveCor Heart Monitor at the American Heart Association Scientific Sessions